How to Help Your Patients Save Money on Apomorphine: A Provider's Guide to Savings Programs

Apomorphine is one of the most effective rescue therapies for advanced Parkinson's disease—but its cost creates a significant access barrier for many patients. Brand Apokyn can retail for over $7,000 for a 15 mL supply, and the new Onapgo infusion device can exceed $8,500–$9,500 per month. Even patients with commercial insurance may face specialty tier copays of hundreds to thousands of dollars. As a prescribing clinician, understanding the savings landscape is critical to ensuring your patients can actually fill and maintain their prescriptions.

The Apomorphine Pricing Landscape: What Patients Are Actually Paying

Understanding pricing helps you advise patients accurately and identify the most impactful savings strategies. Here are the current price benchmarks:

Generic apomorphine injection (TruPharma): Retail ~$1,438 per 3 mL cartridge; with GoodRx from ~$315; with SingleCare ~$454

Brand Apokyn (10 mg/mL, 15 mL): Retail ~$7,228; with manufacturer savings programs, commercially insured patients may pay significantly less

Onapgo (continuous infusion, 5 cartridges/6 cartons): ~$8,500–$9,500 cash; no generic; manufacturer support is the primary cost-reduction tool

Savings Tool 1: Generic Substitution

For Apokyn prescriptions, a generic version of apomorphine hydrochloride injection (10 mg/mL) is available from TruPharma and can substantially reduce costs. When clinically appropriate (and when your patient is on the injection formulation), writing the prescription generically (not brand-required) allows pharmacy substitution. Verify with the patient's specialty pharmacy that they can source the generic.

Note: Generic substitution is not an option for Onapgo (the continuous infusion device), which remains brand-only as a new product.

Savings Tool 2: Supernus Pharmaceuticals Patient Support Programs

Supernus Pharmaceuticals operates Supernus Support (877-727-6596), a hub program for Apokyn and Onapgo that includes:

Copay assistance for commercially insured patients: Can reduce or eliminate specialty tier copays for eligible commercially insured patients. Not available for Medicare or Medicaid beneficiaries.

Patient assistance program (PAP): Provides no-cost medication to uninsured patients who meet financial eligibility criteria. Determined on a case-by-case basis.

Prior authorization support: Supernus Support can assist with PA submissions and appeals, reducing burden on your office staff.

Specialty pharmacy coordination: Can direct prescriptions to in-network specialty pharmacies that stock apomorphine, preventing coverage denials.

Best practice: Enroll every new apomorphine patient in Supernus Support at the time of prescription. Provide patients with the number (877-727-6596) and advise them to call if any access or affordability issues arise.

Savings Tool 3: Optimizing Prior Authorization Documentation

A denied PA forces patients to pay out-of-pocket or go without medication. Strong PA documentation is the most impactful intervention a prescriber can make for cost management. Include in every PA:

Confirmed diagnosis: advanced Parkinson's disease with documented motor fluctuations

Current regimen: full list of Parkinson's medications with doses and duration of use

Trial and failure: evidence that patient has tried and failed or had inadequate response to oral dopamine agonists (required for step therapy plans)

Functional impact: documentation of how off episodes impact activities of daily living, safety, or fall risk

Contraindications to alternatives: documentation of why other advanced therapies (e.g., DBS, VYALEV, Duopa) are not appropriate or have been considered and declined

Savings Tool 4: Medicare Part D Optimization

For Medicare patients, several structural changes in 2025–2026 have improved the affordability of high-cost specialty drugs:

$2,100 annual out-of-pocket cap (2026): Once reached, plan pays 100% for the rest of the year. Patients on apomorphine will typically hit the cap quickly each year.

Medicare Prescription Payment Plan: Allows patients to spread their out-of-pocket costs throughout the year rather than paying large amounts early in the plan year.

Extra Help/LIS: Low-income Medicare beneficiaries may qualify for the Low-Income Subsidy, dramatically reducing specialty drug costs. Screen all Medicare patients for Extra Help eligibility at each annual visit—eligibility thresholds change yearly.

Savings Tool 5: Non-Profit Patient Assistance Organizations

When manufacturer assistance and insurance do not cover sufficient cost, refer patients to:

Patient Advocate Foundation (PAF) Co-Pay Relief: Disease-specific copay assistance funds (patientadvocate.org)

HealthWell Foundation: Provides grants for patient cost-sharing on specialty drugs (healthwellfoundation.org)

NeedyMeds.org: Comprehensive database of patient assistance programs and copay relief options

Recommending medfinder to Reduce Pharmacy Search Burden

Cost is not the only access barrier—availability is equally important. For practices treating complex Parkinson's patients, recommending medfinder for providers can reduce patient distress and office call volume when apomorphine is out of stock at their usual pharmacy. medfinder calls specialty pharmacies near the patient to find which ones have the medication in stock, texting the results directly to the patient.

For a patient-facing version of this savings guide, see: How to save money on apomorphine in 2026: coupons, discounts, and patient assistance.